Supplementary Methods

Cohorts and diagnostic criteria
Patients with Parkinson's disease for whom DNA samples were available were included from seven longitudinal studies conducted at several sites from North America and Europe (table 1): Harvard Biomarker Study (HBS) [1] [2] [3] [4] ; Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) 5, 6 ; Parkinson Research Examination of CEP-1347 Trial/A Longitudinal Follow-up of the PRECEPT Study Cohort (PreCEPT/PostCEPT) 7 ; Cambridgeshire Parkinson's Incidence from GP to Neurologist (CamPaIGN) 8 , Parkinsonism: Incidence, Cognition and Non-motor heterogeneity in Cambridgeshire (PICNICS) 9, 10 , Drug Interaction with Genes in Parkinson's Disease (DIGPD) 11 , PROfiling PARKinson's disease (PROPARK) study 12 , Parkinson's Disease Biomarkers Program (PDBP) 13 and Parkinson's Progression Marker Initiative (PPMI) 14 . Seven cohorts enrolled patients with a diagnosis of PD established according to modified UK PD Society Brain Bank diagnostic criteria as previously reported 4, 5, 7, 9, 11, 12, 15, 16 . Diagnostic criteria in PPMI included a positive DATscan and are described in Ref. 14 . In DATATOP, the eligibility criteria required a clinical diagnosis of early, idiopathic PD (HY stages 1 or 2) with patients not on anti-parkinsonian medications 5 . 
GBA Sequencing Analysis
For the purpose of this analysis we refer to mutations in GBA as those unequivocally identified as pathogenic in Gaucher's disease (GD) 18 as well as E326K, T369M, and E388K mutations. E326K, T369M, and E388K mutations are associated with the risk of PD 3, 19 and are linked to GD when occurring in conjunction with other GBA mutations, but it is controversial whether they are per se pathogenic for GD [20] [21] [22] . Participants were identified as carriers (with one or more GBA mutations) or non-carriers (no GBA mutation). Mutations were identified through targeted next-generation sequencing of the entire GBA coding sequence and flanking intronic regions in four data sets (table 1) . For 173 PD samples in HBS, 332 PD samples in
PreCEPT/PostCEPT and 437 PD samples in DATATOP, as well as 164 PD samples from PROPARK, GBA mutations were systematically identified through full sequencing of the exons and flanking intronic regions of GBA in RefSeq (NM_001005741.2). To avoid sequencing its neighboring pseudogene, the entire locus was amplified in a single long range PCR reaction using the LA PCR Kit version 2.1 (Takara Bio Inc., Otsu, Japan). Template DNA (100 ng) was added to a 50 µL reaction along with primers (final concentration 0.4 µM) with the following sequences: forward primer (5'-CGACTTTACAAACCTCCCTG-3') and reverse primer (5'-CCAGATCCTATCTGTGCTGG-3'), and cycling conditions were 94° for 1 min (1 cycle), 98° for 10 sec followed by 68°C for 15 min (30 cycles), 72°C for 10 min (1 cycle).
This long range PCR assay uses primers that target sequences that uniquely flank GBA and produces a single 7,755 bp PCR product. PCR products were visualized on a 0·8% agarose gel with ethidium bromide to confirm successful amplification, which were then used to construct Illumina ready sequencing libraries using the NexteraXT kit (Illumina, San Diego, US)
following the manufacturer's instructions. Uniquely indexed samples were pooled (up to 384 samples/pool) and run on the from the NeuroX array were used.
Statistical Analysis
Cohort differences in covariate values, and unexplained residual heterogeneity among cohorts in their effects on the dependent variable were addressed. Cochran's Q-test and the I 2 index 27,28 were used to test for the presence and degree of heterogeneity across studies (appendix table 1 ). In addition, differences in continuous and categorical baseline characteristics were compared at baseline between patients with either high and low (cut off 0·196) global cognitive impairment scores using Student's t-tests, and distribution-free Mann-Whitney or Fisher Exact tests, as appropriate (appendix table 2 The Cox proportional hazards statistic was used to estimate the influence of these risk factors on time (years from PD disease onset) to reaching the endpoint of global cognitive impairment (i.e., duration of PD onset at point of global cognitive impairment) during longitudinal follow-up in the discovery population. Age at onset was defined as the patient's age at the time of PD diagnosis for eight studies. PROPARK defined age at onset as the patient's age at the time of first patient-reported motor symptoms. The Cox regression coefficients which were incorporated into the global cognitive impairment risk score each index the hazard rate throughout the time period (12 years) analyzed, which is assumed to be constant throughout that period (the "proportional hazard assumption"). The Cox regression analysis was performed using the coxph function in the Survival package (Version 2.38-1) 30 , and the "Breslow" method was used for handling observations that have tied survival times. The available nine risk factors: gender, age at onset, years of education, GBA The cumulative/dynamic receiver operating characteristic (ROC) curves and area under curves (AUC), sensitivity, specificity was calculated using the timeROC package (Version 0.2) 31, 32 . A bootstrap method was used to calculate the confidence intervals for AUC, and the sweep for the risk threshold averaging method was used to generate confidence bands: we discounted the confidence interval for false positive (1-specificity) and only used the confidence intervals for sensitivity. The Incident/dynamic AUC was calculated using the package RisksetROC package (Version 1.0.4) 33 .
The calculation of the PD cognitive risk score can be best described as a series of steps.
(1) Firstly, the age at diagnosis of PD, years of education (first grade = one year, etc.), current MMSE, current MDS-UPDRS III scores, as well as the values for gender, GBA carrier status, and depression are multiplied by the coefficients from the Cox model (βi corresponding to ith coefficient × Xi corresponding to ith covariate value). The sum of the individual "coefficient × value" products I is calculated.
(2) And the overall mean "coefficient × value" sum G is then calculated from discovery population and combined population in discovery and optimized model, respectively.
Here, is the mean value of ith covariate.
(3) One then calculates the exponent of the individual "coefficient × value" sum minus the overall mean "coefficient × value" sum.
(4) The estimated t-year risk of PD global cognitive impairment risk is formally calculated as 1 minus the survival rate at t years (where s(t) corresponds to baseline survival rate of time t), raised to the power of the B. For example, an estimate of the 10-year risk of global cognitive impairment is calculated as one minus the survival rate at 10 years.
Individual contributions of the seven predictor variables to the score. In order to delineate the individual contributions of the seven predictor variables ---GBA mutation status, age at onset of PD, gender, years of education at enrollment, enrollment MMSE, MDS-UPDRS III scores and depression status ---to the cognitive risk score, we performed a multiple regression of the log-transformed risk score on these seven variables simultaneously, based on 1,350 subjects in the discovery cohort. This analysis provides the percent variance in the risk score linearly accounted for by the model as a whole, i.e., by the optimal ordinary least squares linear combination of the seven predictors, as well as the percent variance accounted for by each predictor uniquely, holding all other predictors constant. The former is equal to the sample multiple R squared and the latter are equal to the square of the semi-partial correlations. The log-transformed risk score was used rather than the raw score to better meet test assumptions.
Hypothetical power analysis for a clinical trial targeting PD patients with high cognitive risk scores. We used a repeated measures ANOVA design of two groups versus four time points (enrollment, one year, two years and three years in study).
One hypothetical group was assigned to placebo and therefore stipulated to have a MMSE (or MoCA) score across time predicted by our mixed effects model, and the second group was assigned to treatment with an experimental drug, which has the hypothetical ability to halt a decline in the scores (all scores set equal to the predicted MMSE (or MoCA) scores at enrollment) 34 . We computed analyses assuming a two-tailed of 0·05 to detect the difference in trajectories across time for the two groups (group × time interaction), and assuming a within group/timepoint standard deviation of two and a one year test/retest correlation of 0·7 as approximate to those values found empirically, with a first-order autoregressive decay across longer periods 34 . The conservative Greenhouse-Geisser correction for degrees of freedom for correlated error was employed. For comparison, analogous computations were performed for a hypothetical clinical trial scenario including any PD patient without enrichment based on the cognitive risk score.
Supplementary Results
A clinical variables-only version of the risk score
A clinical variables-only version of the risk score can be used in settings, where GBA genotyping is not easily obtained, while the clinical-genetic score provides superior prediction where GBA status is available. Because GBA genotyping requires specific laboratory expertise and is not widely available to many clinicians, we explored a variation of the score comprising the six clinical features only (without GBA). This clinical score was informative and predicted global cognitive decline with high accuracy in both the discovery population with an AUC of 0·859 (95% CI, 0·816 -0·898) and the validation population with an AUC of 0·827 (95% CI, 0·741 -0·893) (appendix figure 5A,B) . As for the clinical-genetic score, the clinical score (with its optimal cutoff of 0·199) was built as predictor of global cognitive impairment in the discovery population and replicated in the independent validation population. To evaluate the stability of the clinical score for predicting cognitive impairment and dementia, we repeated the random re-sampling analysis using 10,000 randomly re-sampled training and test sets and rebuilding the model ab initio in the training set in each iteration starting with the seven clinical variables using stepwise backwards elimination based on Akaike's information criterion. Six of the seven clinical variables were stable (with the exception of HY stage) and selected for inclusion into the model in more than 75% of iterations (appendix figure 5C ). The prediction accuracy for dementia had an average AUC of 0·860
(95% CI, 0·803 -0·910) (appendix figure 5D) , sensitivity of 0·764 (95%CI 0·567-0·943), and specificity of 0·743 (95%CI 0·573-0·888) in the test sets. The negative predictive value for dementia in the test sets ranged from 0·875 (95% CI, 0·812-0·926) to 0·906 (95% C.I., 0·872-0·937) based on estimates of prevalence of dementia amongst patients with PD ranging from 31·1% (high quality studies) 35 to 24·5% (all studies) 35 . In a head-to-head comparison with the clinical-genetic score, however, the prediction accuracy of the clinical-only score significantly underperformed compared to that of the clinical-genetic score with p < 0·0001 (appendix figure 5E) . Thus, the informative clinical-only score allows facile implementation in settings where GBA status is not easily obtained, while the clinical-genetic score can provide superior prediction where GBA status is available. For DATATOP published criteria for disabling cognitive impairment were used (cognitive impairment leading to functional impairment) as in Ref. 37 .
DIGPD (France)
Dementia was defined using the diagnostic criteria and checklist recommended for the diagnosis of PD-D by the Movement Disorder task force as in Ref 29 as well as interview-based assessments with the patient and caregiver.
CamPaIGN (UK)
Dementia was diagnosed on the basis of a MMSE of less than or equal to 24 and fulfillment of the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for dementia as previously reported in Ref 16 .
PICNICS (UK)
Dementia was diagnosed using level 1 MDS dementia criteria #The Cochran's Q-test was used to test for residual heterogeneity across studies via R metafor package. I 2 index (100%× (Q-df)/Q) was used to quantify the degree of heterogeneity. *Baseline visits. Depression status (yes:1, no:0)
Baseline Hazard ratio 1·6 (95% CI, 1·02-2·47) p = 0·043
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Figure e4: Time-dependent AUCs of the PD cognitive risk predictor.
The prediction accuracy at various follow-up time points using time-dependent, incident/dynamic ROC curves was stable up to twelve years since onset in both the discovery and validation populations. A decline in the incident/dynamic AUC was observed around the twelve-year time point, which is likely due to the relatively small number of follow-up visits available for these time points in the combined data set. Estimates of the time-dependent, incident/dynamic AUC (t) versus time based on the PD cognitive risk score are shown under the assumption of proportional hazards estimated as in Ref. 33 .
Years since onset The calculator estimates a PD patient's probability of global cognitive impairment for each year following his or her diagnosis of PD (up to ten years from diagnosis). A patient's age at the current visit plus seven predictors (age at diagnosis of PD, years of education (first grade = one year, etc.), current MMSE, current MDS-UPDRS III scores, as well as gender, and GBA carrier status) all of which can be easily obtained in a clinical setting are entered into the calculator. The cognitive risk estimate is then computed based on the patient's current age, the seven predictors, the  coefficients (derived from the Cox model of the combined discovery and validation populations) and mean predictor variable values (from the combined populations) using the survival rate statistic. See appendix for a detailed step by step method. Values for two hypothetical patients are shown for illustrative purposes. Both patients have MMSE scores of 28 in the normal range at the current visit and both are within two years of disease duration. Mr. X, a 67 year-old man, has only one "high risk" factor out of seven, that is, male gender. By contrast, Ms. Y has an elevated risk profile with five of seven risk factors indicating high risk (older age at diagnosis of 74, less education, GBA mutation present, higher current motor score, depression). The green interrupted line indicates the year of the current visit (e.g. two years since diagnosis). Estimated probabilities of cumulative risk of global cognitive impairment are outputted in table format for each year post diagnosis and plotted as line graphs.
While both patients had the same disease duration and same MMSE scores at the current visit, their ten-year risk of global cognitive decline is quite different (22·5% for Mr. X vs. 95·5% for Ms. Y).
